IMNM · Immunome Inc.
$28.54
+0.46 (+1.64%)
At close · Aug 21
Market Cap
$3.27B
Shares
113.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.08
Open$29.13
Day$27.89–29.15
52W close$8.99–29.83
Avg vol 30d1.1M
Short int18.0M · 15.8% float · 23.0d
Short vol63%
DataOct 2020–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
+23%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
92%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+28%
trailing
6-month return
+28%
trailing
YTD return
+31%
this year
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $23 › 200d $22 — 50d above 200d
Institutional flow
Distributing
-0% holders QoQ · +32 funds added
Insider flow
Accumulating
Net +$440 over 90 days · 50% sells
Short interest
Rising
15.83% of float · ▲ +4.3% MoM · 23.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
201 holders — near 3-yr high, broad support
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
−23%
Y/Y
EPS growth
+51%
Y/Y
Free cash flow
$-200.6M
Balance sheet
$653.0M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
+23%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
92%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $23 › 200d $22 — 50d above 200d
Institutional flow
Distributing
-0% holders QoQ · +32 funds added
Insider flow
Accumulating
Net +$440 over 90 days · 50% sells
Short interest
Rising
15.83% of float · ▲ +4.3% MoM · 23.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
201 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $28 · 92%
Range high $30
vs 200-day avg +29%
vs 50-day avg +23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMNM
this stock
Immunome Inc.
|
$3.27B | +30.7% | -23.2% | — | 15.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.4% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMNM | +6.3% | +27.6% | +28.5% | +23.4% | +30.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +8.2% | +24.3% | +17.3% | +21.3% | +18.9% |
Key facts
CIK
1472012
CUSIP
45257U108
13F (30d)
196 filings
192 filers
Visit website
Investor relations